ReNeuron stem cell trial clears first hurdle

An independent data safety monitoring board has signed off on the initial use of ReNeuron's stem cell therapy for stroke, clearing the way for more testing and fueling a jump in the company's share price. "We are delighted that the PISCES stroke clinical trial will now move forward to the next milestone, being the treatment of the remainder of the first patient cohort," said CEO Michael Hunt. "It is both encouraging and reassuring to hear that no safety issues have been observed with the first patient treated with ReN001 and again, we wish him and his family well." Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.